• There are no suggestions because the search field is empty.

Why is Clinical Performance key to a successful IVDR submission?

Author Avatar
Kirsten Van Garsse, Director AR Services and Manager IVD - RA and Maurizio Suppo, Principal Consultant IVD - RA
Clinical
Regulatory Affairs
In Vitro Diagnostics
Did you know that the IVDR mandates robust clinical evidence to support the validity and performance of IVD assays? In this article we'll explore the role of Clinical Performance in a smooth IVDR submission.
 
Why is Clinical Performance key to a successful IVDR submission | QbD Group
4:39

 

The In Vitro Diagnostic Regulation (IVDR) represents a major shift in the regulatory landscape for IVD manufacturers, placing significant emphasis on the need for solid clinical evidence to support the analytical and clinical performance of the assays including the scientific validity of the analytes or markers they detect or quantify. This is a departure from the previous framework, where the importance of clinical data was not as extensively outlined. Under the IVDR, clinical evidence is the foundation upon which a successful regulatory submission is built.

At the heart of the IVDR’s new requirements is Chapter VI, which is entirely dedicated to clinical evidence. In particular, the regulation introduces a new and critical concept of scientific validity, which, alongside analytical and clinical performance, forms the three essential pillars of a solid clinical evidence strategy. 

 

Why is clinical performance so crucial?

 

The most obvious answer should be that unless clinical performance is solidly supported by data, an IVD manufacturer cannot be sure of the robustness of its products. However, a more pragmatic reason is that Notified Bodies are now rigorously scrutinizing clinical evidence as part of their review of technical documentation. A significant portion of deficiencies identified in technical files submitted for IVDR certification are directly related to gaps in clinical data. In many cases, these deficiencies are linked to poorly defined or unclear intended purposes (IP) for the diagnostic assays. If the intended purpose is vague or inadequately defined, it becomes nearly impossible to gather robust clinical evidence, leading to significant delays or rejections during the submission process.

This underscores a critical message for IVD manufacturers: a clear and precise intended purpose is essential to generating credible clinical evidence. Without it, even the most advanced assays may fall short in the eyes of regulatory bodies. Thus, manufacturers must ensure that their intended purposes are not only clearly articulated, but also aligned with the clinical claims they are making.

 
 

The role of Clinical Performance in a smooth IVDR Submission

 

Clinical performance demonstrates that an assay delivers reliable and meaningful results in its intended setting, whether it be a laboratory, near-patient testing, or self-testing device. This aspect of clinical evidence becomes even more critical when considering how stringent IVDR has become in its evaluation of performance studies. For manufacturers, understanding and planning for these performance requirements from the outset is paramount to avoid delays or rejections in the approval process.

At QbD Group, we have witnessed firsthand how a proactive and comprehensive approach to clinical evidence can significantly smooth the IVDR submission process. In particular, the Qarad experts at QbD, have leveraged their years of expertise to help IVD manufacturers refine their clinical performance strategies and navigate the complexities of performance studies.
The experience our experts have accumulated shows that triple-checking clinical evidence—from the intended purpose of the device to the study design and data collection—can make all the difference. By ensuring that the clinical evidence provided is robust, complete, and aligned with regulatory expectations, manufacturers can reduce the risk of deficiencies being flagged by Notified Bodies.

 
 

Support for IVD manufacturers

 

Our upcoming webinar, “Mastering Clinical Performance Studies under IVDR – From Strategy to Delivery,” is designed to equip IVD manufacturers with the knowledge and tools they need to ensure a smooth transition to IVDR compliance. We will delve into the critical aspects of clinical performance, offering insights and guidance from defining your clinical strategy to meeting ISO 20916 requirements and conducting usability studies for near-patient and self-testing devices.

Our team of experts will share strategies for:

  • Defining a strong clinical performance strategy tailored to your assay.
  • Understanding the regulatory requirements for clinical performance studies, including those under ISO 20916.
  • Navigating the complexities of Annex XIV compliance.
  • Conducting effective usability studies for near-patient and self-testing devices.


Whether you are at the beginning of your IVDR submission process or seeking to refine your strategy, we are here to help you master the clinical performance requirements and avoid common pitfalls.

 

 

 

 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Whitepaper

A Complete Guide to Computer System Validation

This guide aims to bring context and define the necessary and appropriate strategies for the validation of computerized systems. Download now.
preview_image
Whitepaper

Digital Health - Exploring the landscape and future opportunities

This whitepaper informs you about digital health, key technology pillars, and new opportunities to anticipate future trends in your healthcare sector.
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Whitepaper

Mobile health on the rise: exploring the regulatory landscape for reimbursement

This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
preview_image
Whitepaper

GAMP 5 Software Validation Approach for GMP, GCP and GLP regulations

Learn how to comply with GMP, GCP, and GLP regulations using the GAMP 5 Software Validation Approach. Download the whitepaper for more insights.
preview_image
Webinar

Mastering Clinical Performance Studies under IVDR

In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
preview_image
Whitepaper

Clinical evidence for In Vitro Diagnostics under IVDR

In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
preview_image
Webinar

Post-Market Surveillance Requirements for Medical Devices and IVDs

Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
preview_image
Whitepaper

21 CFR Part 11 compliance checklist

Want to assess whether a computer system generates electronic records and uses electronic signatures, and whether the system complies with Part 11 of 21 CFR? Download this free checklist.
preview_image
Webinar

Second edition of GAMP 5: A Risk-Based Approach to compliant GxP Computerized Systems

This webinar on demand will tell you more about the second edition of GAMP 5.
preview_image
Whitepaper

GAMP categories for computerized systems: what are they and what are they for?

In this whitepaper, you will learn what GAMP is, what GAMP categories are for, and where to start if you are facing computerized systems validation.
preview_image
Whitepaper

EUDRALEX Volume 4 Annex 11 Compliance Checklist

Assess your computer system's compliance with EudraLex Volume 4 Annex 11 guidelines using our checklist. Download now for GMP assurance.
preview_image
Whitepaper

From V-model to Agile: how to embrace automation as part of the computerized system validation approach

This white paper explores why IT is shifting to agile, focuses on the prevalent Scrum methodology, and concludes with guidance on adapting system validation processes.
preview_image
Webinar

IVDR Extension Explained: Tips & Strategies

Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
preview_image
Case study

The journey toward IVDR compliance for the LVOne device

QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.